Servier to buy Agios’ oncology business for up to $2bn
Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.
Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.
Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.
Swiss drugmaker Novartis has agreed to acquire US-based neuroscience company Cadent Therapeutics for a total potential consideration of $770m.
CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
Eli Lilly has agreed to acquire US-based gene therapy company Prevail Therapeutics for an aggregate value of up to $1.04bn.
Private investment organisation EQT IX has offered to acquire Swedish contract development and manufacturing organisation (CDMO) Recipharm for $2.1bn.
AstraZeneca has agreed to acquire US-based biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.
Gilead Sciences and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash.
Boehringer Ingelheim has agreed to acquire clinical-stage Swiss biotechnology company NBE-Therapeutics for €1.18bn for enhancing its cancer pipeline portfolio.
Cybin, a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction (the “Transaction”).